Pharma BD Deal Intelligence
Edesa Biotech granted KYORIN Pharmaceutical exclusive rights to develop and commercialize paridiprubart (EB05), an anti-TLR4 monoclonal antibody, in Japan for acute respiratory distress syndrome. KYORIN pays Edesa $12 million upfront with up to $134 million in development, regulatory and sales-based milestones plus double-digit royalties on net sales, for total potential consideration of approximately $146 million. KYORIN assumes responsibility for Japanese development, regulatory activities and commercialization; Edesa retains all rights outside Japan, including manufacturing.